BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 188% based on the discounted cash flow analysis.
| Market cap | $1.79 Billion |
|---|---|
| Enterprise Value | $21.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.43 |
| Beta | 0.42 |
| Outstanding Shares | 372,800,000 |
| P/E Ratio | -1.49 |
|---|---|
| PEG | -0.06 |
| Price to Sales | 0.21 |
| Price to Book Ratio | -1.59 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | 10.06 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | -10.1 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.00% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 62.77% |
|---|---|
| Total Invested | $283,748▼ 99.98% |
| Investors Holding | 4▼ 241.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...